AI Tokens
Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

Common-Size Income Statement
Quarterly Data

Eli Lilly & Co., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost of sales -16.12 -14.22 -18.07 -17.48 -17.09 -15.73 -17.47 -17.76 -18.98 -19.20 -19.09 -19.12 -19.58 -21.74 -23.37 -21.20 -22.75 -22.05 -26.53 -25.63 -21.13 -28.98 -27.60
Gross margin 83.88% 85.78% 81.93% 82.52% 82.91% 84.27% 82.53% 82.24% 81.02% 80.80% 80.91% 80.88% 80.42% 78.26% 76.63% 78.80% 77.25% 77.95% 73.47% 74.37% 78.87% 71.02% 72.40%
Research and development -17.41 -16.62 -17.73 -19.71 -19.69 -21.44 -21.48 -22.33 -23.90 -23.99 -28.77 -27.40 -25.36 -28.35 -28.52 -27.33 -25.97 -27.46 -20.62 -23.73 -25.18 -24.55 -24.57
Marketing, selling, and administrative -12.81 -14.93 -14.82 -16.23 -15.57 -17.70 -19.40 -17.92 -18.36 -18.73 -22.27 -20.58 -18.99 -23.16 -25.13 -22.50 -23.25 -25.05 -19.95 -19.90 -23.30 -25.01 -23.16
Acquired in-process research and development -17.14 -12.08 -2.95 -2.74 -3.73 -0.99 -12.35 -1.40 -24.71 -1.37 -1.26 -6.66 -31.32 -1.17 -1.51 -3.29 -0.90 -6.79 -2.12 -5.47 -2.62 -0.64 -4.58
Asset impairment, restructuring, and other special charges -1.24 -3.06 -1.41 -0.44 -2.07 0.00 -0.27 -2.54 -0.71 -3.85 0.00 -0.72 0.00 0.00 0.00 -0.52 -2.97 0.00 0.00 -1.31 0.00 0.00 -3.11
Operating income 35.28% 39.08% 45.03% 43.41% 41.85% 44.14% 29.03% 38.05% 13.34% 32.87% 28.62% 25.53% 4.74% 25.57% 21.47% 25.15% 24.15% 18.65% 30.78% 23.97% 27.78% 20.82% 16.98%
Other, net, income (expense) -0.83 1.17 -0.33 -0.56 -0.76 -0.58 -1.88 -0.81 0.54 -1.75 0.31 1.29 -0.24 -0.44 0.51 3.56 -1.60 -1.84 -4.49 -0.97 -9.39 2.83 4.72
Income before income taxes 34.46% 40.25% 44.70% 42.85% 41.09% 43.56% 27.15% 37.23% 13.89% 31.12% 28.92% 26.82% 4.50% 25.13% 21.98% 28.71% 22.55% 16.81% 26.29% 23.00% 18.39% 23.65% 21.69%
Income taxes -8.01 -9.37 -7.34 -8.44 -9.37 -7.17 -5.47 -4.65 -5.40 -4.87 -3.34 -3.41 -5.10 -3.92 -2.66 -2.17 -1.64 -2.13 -1.93 -1.42 -2.00 -3.02 -1.78
Net income (loss) 26.44% 30.88% 37.36% 34.41% 31.72% 36.38% 21.68% 32.59% 8.48% 26.25% 25.58% 23.41% -0.60% 21.21% 19.32% 26.54% 20.91% 14.68% 24.36% 21.58% 16.39% 20.63% 19.91%

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


The financial trajectory over the observed period is characterized by a significant expansion in profitability margins and an increase in operating leverage. Revenue efficiency has improved consistently, with a marked transition from moderate margins in 2021 to substantially higher profitability levels by 2026.

Gross Margin Expansion
A consistent upward trend is observed in gross margins, which rose from 72.40% in March 2021 to a peak of 85.78% by March 2026. This expansion is mirrored by a corresponding decline in the cost of sales, which decreased from 27.60% to 16.12% over the period. This suggests an increase in production efficiency, pricing power, or a shift toward higher-margin product mixes.
Operating Expense Optimization
Both Research and Development (R&D) and Marketing, Selling, and Administrative (SG&A) expenses show a general downward trend as a percentage of revenue. R&D expenditures fluctuated between 20% and 28% until 2024, subsequently declining to approximately 17% by September 2026. SG&A expenses followed a similar trajectory, decreasing from a range of 20% to 25% in the early period to 12.81% by the end of the series. This indicates that revenue growth is scaling faster than the associated operational costs.
Strategic Investment Volatility
The impact of acquired in-process research and development (IPRD) is characterized by high volatility and periodic spikes. Notable increases occurred in September 2023 (-31.32%), September 2024 (-24.71%), and during the middle of 2026. These spikes frequently coincide with temporary contractions in quarterly operating income, reflecting the cost of strategic acquisitions used to bolster the long-term pipeline.
Operating and Net Income Performance
Operating income margins exhibit a strong overall growth trend, rising from 16.98% in March 2021 to peaks exceeding 45% in 2025, despite the aforementioned volatility from IPRD and special charges. Net income margins followed a similar positive trajectory, starting at 19.91% and reaching a high of 37.36% in March 2026. This growth in the bottom line is partially offset by an increase in the effective tax rate as a percentage of revenue, which grew from roughly 1.78% in early 2021 to between 8% and 9% in 2025 and 2026, likely reflecting the impact of higher taxable income.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?